Durect Completes Dosing of Sufentanil Patch Study, Pain Relief Depot Study

Durect, an emerging specialty pharmaceuticals systems company, has announced the completion of dosing of the Phase I pharmacokinetic study for Durect's Transdur-based sufentanil patch.

The company also announced the completion of dosing of the first cohort of the ongoing Phase II clinical study for Durect's Saber-based postoperative pain relief depot product and is actively enrolling patients in the second cohort.